Highlighted Publications

View a comprehensive list of publications.

2022

  1. Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction.
    Ezerskiy LA, Schoch KM, Sato C, Beltcheva M, Horie K, Rigo F, Martynowicz R, Karch CM, Bateman RJ, Miller TM.
    JCI Insight. 2022 Jan 11;7(1):e152012. doi: 10.1172/jci.insight.152012.
    PMID: 34874917 Free PMC article.
  2. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.
    Sanchez-Sanchez JL, Giudici KV, Guyonnet S, Delrieu J, Li Y, Bateman RJ, Parini A, Vellas B, de Souto Barreto P; MAPT/DSA Group.
    Alzheimers Res Ther. 2022 Jan 7;14(1):5. doi: 10.1186/s13195-021-00940-2.
    PMID: 34996522 Free PMC article.
  3. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer’s Disease.
    Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR.
    J Proteome Res. 2022 Jan 7;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24.
    PMID: 34818016 Free PMC article.
  4. Interactions between weight loss and plasma neurodegenerative markers for determining cognitive decline among community-dwelling older adults.
    Giudici KV, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, Parini A, Li Y, Bateman RJ, Vellas B, Barreto PS; MAPT/DSA group.
    J Gerontol A Biol Sci Med Sci. 2022 Jan 16:glac015. doi: 10.1093/gerona/glac015. Online ahead of print.
    PMID: 35034116
  5. Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated.
    Barthélemy NR, Toth B, Manser PT, Sanabria-Bohórquez S, Teng E, Keeley M, Bateman RJ, Weimer RM, Wildsmith KR.
    J Alzheimers Dis. 2022;85(1):415-429. doi: 10.3233/JAD-210677.
    PMID: 34806603
  6. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study.
    Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ, Joseph-Mathurin N, Feldman R, Fitzpatrick CD, Sparks KP, Levin J, Berman SB, Renton AE, Esposito BT, Fernandez MV, Sung YJ, Lee JH, Klunk WE, Hofmann A, Noble JM, Graff-Radford N, Mori H, Salloway SM, Masters CL, Martins R, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Gordon BA, Benzinger TLS, Fox NC, Schofield PR, Fagan AM, Goate AM, Morris JC, Bateman RJ, Johnson KA, Sperling RA; Dominantly Inherited Alzheimer’s Network Investigators.
    Lancet Neurol. 2022 Feb;21(2):140-152. doi: 10.1016/S1474-4422(21)00375-6.
    PMID: 35065037

2021

  1. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease.
    Horie K, Barthélemy NR, Sato C, Bateman RJ.
    Brain. 2021 Mar 3;144(2):515-527. doi: 10.1093/brain/awaa373.
    PMID: 33283854 Free PMC article.
  2. Item response theory analysis of the Clinical Dementia Rating.
    Li Y, Xiong C, Aschenbrenner AJ, Chang CH, Weiner MW, Nosheny RL, Mungas D, Bateman RJ, Hassenstab J, Moulder KL, Morris JC.
    Alzheimers Dement. 2021 Mar;17(3):534-542. doi: 10.1002/alz.12210. Epub 2020 Nov 20.
    PMID: 33215873 Free PMC article.
  3. Modeling autosomal dominant Alzheimer’s disease with machine learning.
    Luckett PH, McCullough A, Gordon BA, Strain J, Flores S, Dincer A, McCarthy J, Kuffner T, Stern A, Meeker KL, Berman SB, Chhatwal JP, Cruchaga C, Fagan AM, Farlow MR, Fox NC, Jucker M, Levin J, Masters CL, Mori H, Noble JM, Salloway S, Schofield PR, Brickman AM, Brooks WS, Cash DM, Fulham MJ, Ghetti B, Jack CR Jr, Vöglein J, Klunk W, Koeppe R, Oh H, Su Y, Weiner M, Wang Q, Swisher L, Marcus D, Koudelis D, Joseph-Mathurin N, Cash L, Hornbeck R, Xiong C, Perrin RJ, Karch CM, Hassenstab J, McDade E, Morris JC, Benzinger TLS, Bateman RJ, Ances BM; Dominantly Inherited Alzheimer Network (DIAN).
    Alzheimers Dement. 2021 Jun;17(6):1005-1016. doi: 10.1002/alz.12259. Epub 2021 Jan 21.
    PMID: 33480178
  4. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease.
    McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, Haass C, Reiman EM, Sperling R, Tariot PN, Yan R, Masters CL, Vassar R, Lichtenthaler SF.
    Nat Rev Neurol. 2021 Nov;17(11):703-714. doi: 10.1038/s41582-021-00545-1. Epub 2021 Sep 21.
    PMID: 34548654 Review.
  5. The informed road map to prevention of Alzheimer Disease: A call to arms.
    McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ.
    Mol Neurodegener. 2021 Jul 21;16(1):49. doi: 10.1186/s13024-021-00467-y.
    PMID: 34289882 Free PMC article. Review.
  6. Dominantly inherited Alzheimer’s disease in Latin America: Genetic heterogeneity and clinical phenotypes.
    Llibre-Guerra JJ, Li Y, Allegri RF, Mendez PC, Surace EI, Llibre-Rodriguez JJ, Sosa AL, Aláez-Verson C, Longoria EM, Tellez A, Carrillo-Sánchez K, Flores-Lagunes LL, Sánchez V, Takada LT, Nitrini R, Ferreira-Frota NA, Benevides-Lima J, Lopera F, Ramírez L, Jiménez-Velázquez I, Schenk C, Acosta D, Behrens MI, Doering M, Ziegemeier E, Morris JC, McDade E, Bateman RJ.
    Alzheimers Dement. 2021 Apr;17(4):653-664. doi: 10.1002/alz.12227. Epub 2020 Nov 23.
    PMID: 33226734
  7. Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease.
    Smith RX, Strain JF, Tanenbaum A, Fagan AM, Hassenstab J, McDade E, Schindler SE, Gordon BA, Xiong C, Chhatwal J, Jack C Jr, Karch C, Berman S, Brosch JR, Lah JJ, Brickman AM, Cash DM, Fox NC, Graff-Radford NR, Levin J, Noble J, Holtzman DM, Masters CL, Farlow MR, Laske C, Schofield PR, Marcus DS, Morris JC, Benzinger TLS, Bateman RJ, Ances BM.
    Brain Connect. 2021 Apr;11(3):239-249. doi: 10.1089/brain.2020.0808. Epub 2021 Mar 31.
    PMID: 33430685
  8. The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease.
    Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M.
    Mol Psychiatry. 2021 Feb;26(2):614-628. doi: 10.1038/s41380-019-0404-6. Epub 2019 Mar 21.
    PMID: 30899092 Free PMC article.
  9. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K, McCullough A, Franklin EE, Hornbeck R, Gordon B, Sharma V, Cruchaga C, Goate A, Karch C, McDade E, Xiong C, Bateman RJ, Ghetti B, Ringman JM, Chhatwal J, Masters CL, McLean C, Lashley T, Su Y, Koeppe R, Jack C, Klunk WE, Morris JC, Perrin RJ, Cairns NJ, Benzinger TLS.
    Acta Neuropathol. 2021 Oct;142(4):689-706. doi: 10.1007/s00401-021-02342-y. Epub 2021 Jul 28.
    PMID: 34319442
  10. Cross-Sectional and Longitudinal Associations Between Plasma Neurodegenerative Biomarkers and Physical Performance Among Community-Dwelling Older Adults.
    He L, de Souto Barreto P, Giudici KV, Aggarwal G, Nguyen AD, Morley JE, Li Y, Bateman RJ, Vellas B; MAPT/DSA Group.
    J Gerontol A Biol Sci Med Sci. 2021 Sep 13;76(10):1874-1881. doi: 10.1093/gerona/glaa284.
    PMID: 33186456
  11. Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease.
    Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) Research Group.
    Nat Commun. 2021 Sep 9;12(1):5346. doi: 10.1038/s41467-021-25492-9.
    PMID: 34504080 Free PMC article.
  12. Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N, Wang G, Kantarci K, Jack CR Jr, McDade E, Hassenstab J, Blazey TM, Gordon BA, Su Y, Chen G, Massoumzadeh P, Hornbeck RC, Allegri RF, Ances BM, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Chui HC, Correia S, Cruchaga C, Farlow MR, Fox NC, Fulham M, Ghetti B, Graff-Radford NR, Johnson KA, Karch CM, Laske C, Lee AKW, Levin J, Masters CL, Noble JM, O’Connor A, Perrin RJ, Preboske GM, Ringman JM, Rowe CC, Salloway S, Saykin AJ, Schofield PR, Shimada H, Shoji M, Suzuki K, Villemagne VL, Xiong C, Yakushev I, Morris JC, Bateman RJ, Benzinger TLS; Dominantly Inherited Alzheimer Network.
    Neurology. 2021 Mar 23;96(12):e1632-e1645. doi: 10.1212/WNL.0000000000011542. Epub 2021 Jan 25.
    PMID: 33495373 Free PMC article.
  13. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
    Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C.
    Neurology. 2021 Nov 2;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 9.
    PMID: 34504028
  14. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.
    Sato C, Mallipeddi N, Ghoshal N, Wright BA, Day GS, Davis AA, Kim AH, Zipfel GJ, Bateman RJ, Gabelle A, Barthélemy NR.
    Ann Clin Transl Neurol. 2021 Sep;8(9):1817-1830. doi: 10.1002/acn3.51435. Epub 2021 Aug 2.
    PMID: 34342183 Free PMC article.
  15. Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease.
    Ewers M, Luan Y, Frontzkowski L, Neitzel J, Rubinski A, Dichgans M, Hassenstab J, Gordon BA, Chhatwal JP, Levin J, Schofield P, Benzinger TLS, Morris JC, Goate A, Karch CM, Fagan AM, McDade E, Allegri R, Berman S, Chui H, Cruchaga C, Farlow M, Graff-Radford N, Jucker M, Lee JH, Martins RN, Mori H, Perrin R, Xiong C, Rossor M, Fox NC, O’Connor A, Salloway S, Danek A, Buerger K, Bateman RJ, Habeck C, Stern Y, Franzmeier N; Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer Network.
    Brain. 2021 Aug 17;144(7):2176-2185. doi: 10.1093/brain/awab112. PMID: 33725114
  16. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease.
    Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit.
    Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21.
    PMID: 34155411 Clinical Trial.
  17. Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.
    Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, Chhatwal JP, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman JM, Fox NC, Salloway S, Schofield PR, Martins R, Vöglein J, Morris JC; Dominantly Inherited Alzheimer’s Network.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12505. Online ahead of print.
    PMID: 34854530
  18. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
    Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Leslie SM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ.
    Neurology. 2021 Dec 14:10.1212/WNL.0000000000013211. doi: 10.1212/WNL.0000000000013211. Online ahead of print.
    PMID: 34906975
  19. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.
    Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, Reiman EM, Palmqvist S, Dage JL, Beach TG, Hansson O.
    EMBO Mol Med. 2021 Jun 7;13(6):e14022. doi: 10.15252/emmm.202114022. Epub 2021 May 5.
    PMID: 33949133 Free PMC article.
  20. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
    Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O.
    JAMA Neurol. 2021 Nov 1;78(11):1375-1382. doi: 10.1001/jamaneurol.2021.3180.
    PMID: 34542571 Free PMC article.
  21. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer’s disease: a cross-sectional study.
    Fagan AM, Henson RL, Li Y, Boerwinkle AH, Xiong C, Bateman RJ, Goate A, Ances BM, Doran E, Christian BT, Lai F, Rosas HD, Schupf N, Krinsky-McHale S, Silverman W, Lee JH, Klunk WE, Handen BL, Allegri RF, Chhatwal JP, Day GS, Graff-Radford NR, Jucker M, Levin J, Martins RN, Masters CL, Mori H, Mummery CJ, Niimi Y, Ringman JM, Salloway S, Schofield PR, Shoji M, Lott IT; Alzheimer’s Biomarker Consortium–Down Syndrome; Dominantly Inherited Alzheimer Network.
    Lancet Neurol. 2021 Aug;20(8):615-626. doi: 10.1016/S1474-4422(21)00139-3.
    PMID: 34302786
  22. The global Alzheimer’s Association round robin study on plasma amyloid β methods.
    Pannee J, Shaw LM, Korecka M, Waligorska T, Teunissen CE, Stoops E, Vanderstichele HMJ, Mauroo K, Verberk IMW, Keshavan A, Pesini P, Sarasa L, Pascual-Lucas M, Fandos N, Allué JA, Portelius E, Andreasson U, Yoda R, Nakamura A, Kaneko N, Yang SY, Liu HC, Palme S, Bittner T, Mawuenyega KG, Ovod V, Bollinger J, Bateman RJ, Li Y, Dage JL, Stomrud E, Hansson O, Schott JM, Blennow K, Zetterberg H.
    Alzheimers Dement (Amst). 2021 Oct 14;13(1):e12242. doi: 10.1002/dad2.12242. eCollection 2021.
    PMID: 34692980 Free PMC article.
  23. Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study.
    Raffin J, Rolland Y, Aggarwal G, Nguyen AD, Morley JE, Li Y, Bateman RJ, Vellas B, Barreto PS; MAPT/DSA Group.
    J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):1382-1390. doi: 10.1093/gerona/glab094. PMID: 33864068 Clinical Trial.
  24. Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer’s disease.
    Keret O, Staffaroni AM, Ringman JM, Cobigo Y, Goh SM, Wolf A, Allen IE, Salloway S, Chhatwal J, Brickman AM, Reyes-Dumeyer D, Bateman RJ, Benzinger TLS, Morris JC, Ances BM, Joseph-Mathurin N, Perrin RJ, Gordon BA, Levin J, Vöglein J, Jucker M, la Fougère C, Martins RN, Sohrabi HR, Taddei K, Villemagne VL, Schofield PR, Brooks WS, Fulham M, Masters CL, Ghetti B, Saykin AJ, Jack CR, Graff-Radford NR, Weiner M, Cash DM, Allegri RF, Chrem P, Yi S, Miller BL, Rabinovici GD, Rosen HJ; Dominantly Inherited Alzheimer Network.
    Alzheimers Dement (Amst). 2021 Jul 5;13(1):e12197. doi: 10.1002/dad2.12197. eCollection 2021. PMID: 34258377 Free PMC article.
  25. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE.
    Mol Neurodegener. 2021 May 1;16(1):30. doi: 10.1186/s13024-021-00451-6.
    PMID: 33933117 Free PMC article.
  26. Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.
    Tosun D, Veitch D, Aisen P, Jack CR Jr, Jagust WJ, Petersen RC, Saykin AJ, Bollinger J, Ovod V, Mawuenyega KG, Bateman RJ, Shaw LM, Trojanowski JQ, Blennow K, Zetterberg H, Weiner MW.
    Brain Commun. 2021 Feb 2;3(2):fcab008. doi: 10.1093/braincomms/fcab008. eCollection 2021.
    PMID: 33842885 Free PMC article.
  27. Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation.
    Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, Taddei K, Gardener S, Masters CL, Schofield PR, Multhaup G, Benzinger TLS, Morris JC, Bateman RJ, Greenberg SM, van Buchem MA, Stoops E, Vanderstichele H, Teunissen CE, Hankey GJ, Wermer MJH, Sohrabi HR, Martins RN, The Dominantly Inherited Alzheimer Network.
    Int J Mol Sci. 2021 Mar 13;22(6):2931. doi: 10.3390/ijms22062931.
    PMID: 33805778 Free PMC article.
  28. Corrigendum to: CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease.
    Horie K, Barthélemy NR, Sato C, Bateman RJ.
    Brain. 2021 Oct 22;144(9):e82. doi: 10.1093/brain/awab227. PMID: 34215872 Free PMC article. No abstract available.

Benchmark lab publications from 2020 and earlier

  1. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020 Nov 2;217(11):e20200861. doi: 10.1084/jem.20200861. PMID: 32725127; PMCID: PMC7596823. https://pubmed.ncbi.nlm.nih.gov/32725127/
  2. Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, Salloway S, Schofield PR, Masters CL, Martins RN, O’Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network. A soluble phosphorylated tau signature links tau, amyloid and the evolution stages of dominantly inherited Alzheimer’s disease. Nat Med. 2020 Mar;26(3):398-407. doi: 10.1038/s41591-020-0781-z. PMID: 32161412. PMCID: PMC7309367
    https://pubmed.ncbi.nlm.nih.gov/32161412/
  3. Budelier MM, Bateman RJ. Biomarkers of Alzheimer Disease. J Appl Lab Med. 2020 Jan 5(1):194-208. doi: 10.1373/jalm.2019.030080. PMID: 31843944. PMCID: PMC2746147 https://pubmed.ncbi.nlm.nih.gov/31843944/
  4. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.  Neurology, 2019 Aug 1. Doi: 10.1212/WNL.000000000000808a [Epub ahead of print] PMID: 31371569. PMCID: PMC6946467 https://pubmed.ncbi.nlm.nih.gov/31371569/
  5. Paterson RW, Gabelle A, Lucey BP, Barthélemy NR, Leckey CA, Hirtz C, Lehmann S, Sato C, Patterson BW, West T, Yarasheski K, Rohrer JD, Wildburger NC, Schott JM, Karch CM, Wray S, Miller TM, Elbert DL, Zetterberg H, Fox NC, Bateman RJ. SILK studies – capturing the turnover of proteins linked to neurodegenerative diseases. Nat Rev Neurol. 2019 Jul;15(7):419-427. doi: 10.1038/s41582-019-0222-0. Epub 2019 Jun 20. Review. PMID: 31222062. PMCID: PMC6876864. https://pubmed.ncbi.nlm.nih.gov/31222062/
  6. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21. PMID: 31062827. PMCID not required. https://pubmed.ncbi.nlm.nih.gov/31062827/
  7. Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018 May 16;98(4):861-864. doi: 10.1016/j.neuron.2018.04.035. PMID: 29772204. PMCID: PMC6192252. https://pubmed.ncbi.nlm.nih.gov/29772204/
  8. Wildburger NC, Gyngard F, Guillermier C, Patterson BW, Elbert D, Mawuenyega KG, Schneider T, Green K, Roth R, Schmidt RE, Cairns NJ, Benzinger TLS, Steinhauser ML, Bateman RJ. Amyloid-β plaques in clinical Alzheimer’s Disease brain incorporate stable isotope tracer in vivo and exhibit nanoscale heterogeneity. Front Neurol 2018; 22:169. PMID: 29623063; PMCID: PMC5874304 https://pubmed.ncbi.nlm.nih.gov/29623063/
  9. Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018 Mar 21;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015. PMID: 29566794. PMCID: PMC6137722. https://pubmed.ncbi.nlm.nih.gov/29566794/
  10. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017 Jul 11. pii: S1552-5260(17)32518-9. doi: 10.1016/j.jalz.2017.06.2266. PMID: 28734653. PMCID: PMC5567785. https://pubmed.ncbi.nlm.nih.gov/28734653/
  11. Baker-Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, Liao F, Jiang H, Holtzman D, Cairns NJ, Morris JC, Bateman RJ. Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. J Biol Chem. 2016 Dec 30;291(53):27204-27218. doi: 10.1074/jbc.M116.721779. Epub 2016 Oct 28. PMID: 27793990; PMCID: PMC5207148. https://pubmed.ncbi.nlm.nih.gov/27793990/
  12. Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther. 2015 Jul 29;7(1):53. doi: 10.1186/s13195-015-0136-z. eCollection 2015. PMID: 26225140. PMCID: PMC4518529 https://pubmed.ncbi.nlm.nih.gov/26225140/
  13. Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W, Zhang L, Goate A, Benzinger T, Morris JC, Holtzman D, Bateman RJ. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015 Sep;78(3):439-53. doi: 10.1002/ana.24454. Epub 2015 Jul 20. PMID: 26040676; PMCID: PMC4546566. https://pubmed.ncbi.nlm.nih.gov/26040676/
  14. Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, Ovod V, Munsell LY, Mawuenyega KG, Miller-Thomas MM, Moran CJ, Cross DT 3rd, Derdeyn CP, Bateman RJ. Amyloid-β efflux from the CNS into the plasma. Ann Neurol. 2014 Sep 10. doi: 10.1002/ana.24270. PMID: 25205593. PMCID: PMC4355962 https://pubmed.ncbi.nlm.nih.gov/25205593/
  15. Lucey BP, Bateman RJ. Amyloid-β diurnal pattern: possible role of sleep in Alzheimer’s disease pathogenesis. Neurobiol Aging 2014; 35:S29-S34. PMID: 24910393 https://pubmed.ncbi.nlm.nih.gov/24910393/
  16. Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, Pyatkivskyy Y, Wildsmith KR, Kasten T, Mathers P, Dancho M, Lennox C, Smith BE, Gilberto D, McLoughlin D, Holder DJ, Stamford AW, Yarasheski KE, Kennedy ME, Savage MJ, Bateman RJ. CNS amyloid-β, soluble APP-α and –β kinetics during BACE inhibition. J Neurosci 2014 34:8336-46. PMID: 24920637. PMCID:PMC4051982 https://pubmed.ncbi.nlm.nih.gov/24920637/
  17. Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One 2014; Mar 19:9(3):e89998. PMID: 24646516; PMCID: PMC3960093 https://pubmed.ncbi.nlm.nih.gov/24646516/
  18. Wardlaw S, Burant CF, Klein S, Meece K, White A, Kasten T, Lucey BP, Bateman RJ. Continuous 24-Hour leptin, proopiomelanocortin and amino acid measurements in human cerebrospinal fluid: correlations with plasma leptin, soluble leptin receptor and amino acid levels. J Clin Endocrinol Metab; 2014 Mar 26:jc20134087. [Epub ahead of print]. PMID: 24670082. PMCID:PMC4079306 https://pubmed.ncbi.nlm.nih.gov/24670082/
  19. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TLS, Bateman RJ. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 2013; 5, 189ra77 doi: 10.1126/scitranslmed.3005615. PMID: 23761040; PMCID: PMC3838868 https://pubmed.ncbi.nlm.nih.gov/23761040/
  20. Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-beta isoform metabolism quantitation by stable isotope labeled kinetics. Anal Biochem 2013; 440:56-62. PMID: 23714261; PMCID: PMC3749773 https://pubmed.ncbi.nlm.nih.gov/23714261/
  21. Ovod V, Scott EA, Flake MM, Parker SR, Bateman RJ, Elbert DL. Exposure of the lysine in the gamma chain dodecapeptide of human fibrinogen is not enhanced by adsorption to poly (ethylene terephthalate) as measured by biotinylation and mass spectrometry. J Biomed Mater Res A 2012; 100:622-31. PMID: 22213354; PMCID: PMC3266446 https://pubmed.ncbi.nlm.nih.gov/22213354/
  22. Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease. J Alzheimers Dis 2012; 31:335-41. PMID:22531418; PMCID: PMC6309706 https://pubmed.ncbi.nlm.nih.gov/22531418/
  23. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. Βeta-Amyloid dynamics in human plasma. Arch Neurol 2012; 69:1591-7. PMID:23229043; PMCID: PMC3808092 https://pubmed.ncbi.nlm.nih.gov/23229043/
  24. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367:795-804. PMID:22784036; PMCID: PMC3474597 https://pubmed.ncbi.nlm.nih.gov/22784036/
  25. Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim, J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, Holtzman DM, Bateman RJ. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 2012; 7(6):e38013. Epub 2012 Jun 4. PMID:22675504; PMCID: PMC3366983 https://pubmed.ncbi.nlm.nih.gov/22675504/
  26. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju Y, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol 2012 Jan; 69 (1):51-8. PMID:21911660; PMCID: PMC3254706 https://pubmed.ncbi.nlm.nih.gov/21911660/
  27. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS amyloid-β in Alzheimer’s disease. Science 2010; 330 (6012): PMID: 21148344; PMCID:PMC3073454 https://pubmed.ncbi.nlm.nih.gov/21148344/
  28. Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010; 30:6743-50. PMID:20463236; PMCID:PMC2913973 https://pubmed.ncbi.nlm.nih.gov/20463236/
  29. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66:48-54. PMID:19360898; PMCID:PMC2730994 https://pubmed.ncbi.nlm.nih.gov/19360898/
  30. Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease. Neurotherapeutics 2008; 5:381-90. PMID:18625449; PMCID:PMC2588423 https://pubmed.ncbi.nlm.nih.gov/18625449/
  31. Bateman RJ, Eidelberg D. Testing a test for Alzheimer disease. Neurology. 2007 Feb 13;68(7):482-3. PubMed PMID: 17296912. https://pubmed.ncbi.nlm.nih.gov/17296912/
  32. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12:856-61. PMID:1679555; PMCID:PMC2983090 https://pubmed.ncbi.nlm.nih.gov/16799555/